Found: 82
Select item for more details and to access through your institution.
Safety of Inactivated Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitors.
- Published in:
- Clinical Infectious Diseases, 2020, v. 70, n. 2, p. 193, doi. 10.1093/cid/ciz202
- By:
- Publication type:
- Article
Checkpoint blocking antibodies in cancer immunotherapy.
- Published in:
- FEBS Letters, 2014, v. 588, n. 2, p. 368, doi. 10.1016/j.febslet.2013.10.015
- By:
- Publication type:
- Article
Perspectives in melanoma: Meeting report from the Melanoma Bridge (30 November-2 December, 2017, Naples, Italy).
- Published in:
- 2018
- By:
- Publication type:
- research
Definite regression of cutaneous melanoma metastases upon addition of topical contact sensitizer diphencyprone to immune checkpoint inhibitor treatment.
- Published in:
- Experimental Dermatology, 2016, v. 25, n. 7, p. 553, doi. 10.1111/exd.13030
- By:
- Publication type:
- Article
LAG-3 expression on peripheral blood cells identifies patients with poorer outcomes after immune checkpoint blockade.
- Published in:
- Science Translational Medicine, 2021, v. 13, n. 608, p. 1, doi. 10.1126/scitranslmed.abf5107
- By:
- Publication type:
- Article
MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma.
- Published in:
- Science Translational Medicine, 2018, v. 10, n. 450, p. 1, doi. 10.1126/scitranslmed.aar3342
- By:
- Publication type:
- Article
The Ice Cream Man.
- Published in:
- JAMA: Journal of the American Medical Association, 2011, v. 305, n. 15, p. 1518, doi. 10.1001/jama.2011.371
- By:
- Publication type:
- Article
The Spectrum of Serious Infections Among Patients Receiving Immune Checkpoint Blockade for the Treatment of Melanoma.
- Published in:
- Clinical Infectious Diseases, 2016, v. 63, n. 11, p. 1490, doi. 10.1093/cid/ciw539
- By:
- Publication type:
- Article
Survival Outcomes After Metastasectomy in Melanoma Patients Categorized by Response to Checkpoint Blockade.
- Published in:
- Annals of Surgical Oncology: An Oncology Journal for Surgeons, 2020, v. 27, n. 4, p. 1180, doi. 10.1245/s10434-019-08099-9
- By:
- Publication type:
- Article
Liver resection and ablation for metastatic melanoma: A single center experience.
- Published in:
- Journal of Surgical Oncology, 2015, v. 111, n. 8, p. 962, doi. 10.1002/jso.23929
- By:
- Publication type:
- Article
Meta-Analysis of Quality of Life in Cancer Patients Treated With Immune Checkpoint Inhibitors.
- Published in:
- JNCI: Journal of the National Cancer Institute, 2022, v. 114, n. 6, p. 808, doi. 10.1093/jnci/djab171
- By:
- Publication type:
- Article
Recommendations for Testing and Treating Outpatient Cancer Patients in the Era of COVID-19.
- Published in:
- 2021
- By:
- Publication type:
- journal article
Thinking Critically About Classifying Adverse Events: Incidence of Pancreatitis in Patients Treated With Nivolumab + Ipilimumab.
- Published in:
- 2017
- By:
- Publication type:
- journal article
Neuropilin-1 as therapeutic target for malignant melanoma.
- Published in:
- Frontiers in Oncology, 2015, p. 1, doi. 10.3389/fonc.2015.00125
- By:
- Publication type:
- Article
CTLA-4 and PD-1 pathway blockade: combinations in the clinic.
- Published in:
- Frontiers in Oncology, 2015, v. 5, p. 1, doi. 10.3389/fonc.2014.00385
- By:
- Publication type:
- Article
Emerging Tissue and Blood-Based Biomarkers that may Predict Response to Immune Checkpoint Inhibition.
- Published in:
- Current Oncology Reports, 2016, v. 18, n. 4, p. 1, doi. 10.1007/s11912-016-0509-x
- By:
- Publication type:
- Article
Checkpoint Modulation in Melanoma: An Update on Ipilimumab and Future Directions.
- Published in:
- Current Oncology Reports, 2013, v. 15, n. 5, p. 500, doi. 10.1007/s11912-013-0337-1
- By:
- Publication type:
- Article
Mucosal Melanoma: Pathogenesis, Clinical Behavior, and Management.
- Published in:
- Current Oncology Reports, 2012, v. 14, n. 5, p. 441, doi. 10.1007/s11912-012-0244-x
- By:
- Publication type:
- Article
CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 10, p. 1, doi. 10.2967/jnumed.121.262485
- By:
- Publication type:
- Article
CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 9, p. 1, doi. 10.2967/jnumed.121.262485
- By:
- Publication type:
- Article
Title: CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 8, p. 1, doi. 10.2967/jnumed.121.262485
- By:
- Publication type:
- Article
Title: CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 7, p. 1, doi. 10.2967/jnumed.121.262485
- By:
- Publication type:
- Article
CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 6, p. 1, doi. 10.2967/jnumed.121.262485
- By:
- Publication type:
- Article
CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 5, p. 1, doi. 10.2967/jnumed.121.262485
- By:
- Publication type:
- Article
CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 3, p. 1, doi. 10.2967/jnumed.121.262485
- By:
- Publication type:
- Article
CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 2, p. 1, doi. 10.2967/jnumed.121.262485
- By:
- Publication type:
- Article
CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.
- Published in:
- Journal of Nuclear Medicine, 2022, v. 63, n. 1, p. 1, doi. 10.2967/jnumed.121.262485
- By:
- Publication type:
- Article
Title: CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 12, p. 1, doi. 10.2967/jnumed.121.262485
- By:
- Publication type:
- Article
CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 11, p. 1, doi. 10.2967/jnumed.121.262485
- By:
- Publication type:
- Article
CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of <sup>89</sup>Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.
- Published in:
- Journal of Nuclear Medicine, 2021, v. 62, n. 10, p. 1, doi. 10.2967/jnumed.121.262485
- By:
- Publication type:
- Article
First-in-human imaging with <sup>89</sup>Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting.
- Published in:
- Journal of Nuclear Medicine, 2019, v. 60, n. 12, p. 1, doi. 10.2967/jnumed.119.229781
- By:
- Publication type:
- Article
Immune‐related Adverse Events in Cancer Patients.
- Published in:
- Academic Emergency Medicine, 2018, v. 25, n. 7, p. 819, doi. 10.1111/acem.13443
- By:
- Publication type:
- Article
Prevalence of Enteric Infections in Patients on Immune Checkpoint Inhibitors and Impact on Management and Outcomes.
- Published in:
- Oncologist, 2024, v. 29, n. 1, p. 36, doi. 10.1093/oncolo/oyad226
- By:
- Publication type:
- Article
Exocrine Pancreatic Insufficiency Induced by Immune Checkpoint Inhibitors.
- Published in:
- Oncologist, 2023, v. 28, n. 12, p. 1085, doi. 10.1093/oncolo/oyad150
- By:
- Publication type:
- Article
Decision-Making and Health-Related Quality of Life in Patients with Melanoma Considering Adjuvant Immunotherapy.
- Published in:
- Oncologist, 2023, v. 28, n. 4, p. 351, doi. 10.1093/oncolo/oyac266
- By:
- Publication type:
- Article
Associations Between Race/Ethnicity, Language, and Enrollment on Cancer Research Studies.
- Published in:
- Oncologist, 2023, v. 28, n. 2, p. 131, doi. 10.1093/oncolo/oyac218
- By:
- Publication type:
- Article
Efficacy of Infliximab Dose Escalation in Patients with Refractory Immunotherapy-Related Colitis: A Case Series.
- Published in:
- Oncologist, 2022, v. 27, n. 4, p. e350, doi. 10.1093/oncolo/oyac019
- By:
- Publication type:
- Article
Eosinophilic Fasciitis Following Checkpoint Inhibitor Therapy: Four Cases and a Review of Literature.
- Published in:
- Oncologist, 2020, v. 25, n. 2, p. 140, doi. 10.1634/theoncologist.2019-0508
- By:
- Publication type:
- Article
Myocarditis Surveillance in Patients with Advanced Melanoma on Combination Immune Checkpoint Inhibitor Therapy: The Memorial Sloan Kettering Cancer Center Experience.
- Published in:
- Oncologist, 2019, v. 24, n. 5, p. e196, doi. 10.1634/theoncologist.2019-0040
- By:
- Publication type:
- Article
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.
- Published in:
- Oncologist, 2016, v. 21, n. 10, p. 1230, doi. 10.1634/theoncologist.2016-0055
- By:
- Publication type:
- Article
Prognosis of Mucosal, Uveal, Acral, Nonacral Cutaneous, and Unknown Primary Melanoma From the Time of First Metastasis.
- Published in:
- Oncologist, 2016, v. 21, n. 7, p. 848, doi. 10.1634/theoncologist.2015-0522
- By:
- Publication type:
- Article
Ipilimumab for Patients With Advanced Mucosal Melanoma.
- Published in:
- Oncologist, 2013, v. 18, n. 6, p. 726, doi. 10.1634/theoncologist.2012-0464
- By:
- Publication type:
- Article
Peripheral blood clinical laboratory variables associated with outcomes following combination nivolumab and ipilimumab immunotherapy in melanoma.
- Published in:
- Cancer Medicine, 2018, v. 7, n. 3, p. 690, doi. 10.1002/cam4.1356
- By:
- Publication type:
- Article
Recent Advances in the Field of Artificial Intelligence for Precision Medicine in Patients with a Diagnosis of Metastatic Cutaneous Melanoma.
- Published in:
- Diagnostics (2075-4418), 2023, v. 13, n. 22, p. 3483, doi. 10.3390/diagnostics13223483
- By:
- Publication type:
- Article
Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors.
- Published in:
- Nature Communications, 2021, v. 12, n. 1, p. 1, doi. 10.1038/s41467-021-20935-9
- By:
- Publication type:
- Article
Melanoma brain metastasis presentation, treatment, and outcomes in the age of targeted and immunotherapies.
- Published in:
- Cancer (0008543X), 2021, v. 127, n. 12, p. 2062, doi. 10.1002/cncr.33459
- By:
- Publication type:
- Article
High neutrophil-to-lymphocyte ratio (NLR) is associated with treatment failure and death in patients who have melanoma treated with PD-1 inhibitor monotherapy.
- Published in:
- 2020
- By:
- Publication type:
- journal article
Melanoma and non-melanoma skin cancers in hairy cell leukaemia: a Surveillance, Epidemiology and End Results population analysis and the 30-year experience at Memorial Sloan Kettering Cancer Center.
- Published in:
- British Journal of Haematology, 2015, v. 171, n. 1, p. 84, doi. 10.1111/bjh.13528
- By:
- Publication type:
- Article
On being less tolerant: Enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation.
- Published in:
- Science Translational Medicine, 2015, v. 7, n. 280, p. 1, doi. 10.1126/scitranslmed.3010274
- By:
- Publication type:
- Article
Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway.
- Published in:
- Pharmacogenomics & Personalized Medicine, 2014, v. 7, p. 357, doi. 10.2147/PGPM.S53163
- By:
- Publication type:
- Article